The Challenge of Finding a Cure for HIV Infection-Reference-Cited by-同舟云学术

The Challenge of Finding a Cure for HIV Infection

Published:2009-03-06 Issue:5919 Volume:323 Page:1304-1307
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Richman Douglas D.¹²³⁴⁵,Margolis David M.¹²³⁴⁵,Delaney Martin¹²³⁴⁵,Greene Warner C.¹²³⁴⁵,Hazuda Daria¹²³⁴⁵,Pomerantz Roger J.¹²³⁴⁵

Affiliation:

1. San Diego VA Healthcare System and University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093–0679, USA.

2. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

3. Project Inform, 1375 Mission Street, San Francisco, CA 94103, USA.

4. Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, and University of California at San Francisco, San Francisco, CA 94143, USA.

5. Merck and Co., West Point, PA 19486, USA.

Abstract

Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4 + lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

2. The Cycle of Human Herpes Simplex Virus Infection: Virus Transport and Immune Control

3. World Health Organization Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2008 (World Health Organization Geneva June 2008); www.who.int/hiv/mediacentre/2008progressreport/en/index.html.

4. Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy

5. Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy

Cited by 715 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation;Journal of Experimental Medicine;2024-01-25

2. Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase;European Journal of Medicinal Chemistry;2023-12

3. siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight;AAPS PharmSciTech;2023-08-11

4. Scopoletin Reactivates Latent HIV-1 by Inducing NF-κB Expression without Global T Cell Activation;International Journal of Molecular Sciences;2023-08-10

5. Impact of misclassified defective proviruses on HIV reservoir measurements;Nature Communications;2023-07-13